Takeda Faces Verdict in AMITIZA® Antitrust Case

Takeda Pharmaceutical Company Limited has announced a jury verdict against it in an antitrust litigation related to AMITIZA® (lubiprostone) in the U.S. The jury awarded nearly USD 885 million in single damages, impacting wholesalers and individual retailers. Damages will be trebled under U.S. antitrust law upon judgment entry. Plaintiffs argue the 2014 settlement with Par Pharmaceutical over its generic formulation of AMITIZA was anticompetitive.

Takeda plans to challenge the verdict and believes there were errors during the trial. The company is currently evaluating the provision to be recognized in its FY2025 financial statements. Takeda reassures that this outcome will not affect its core FY2025 financial results.

Takeda’s AMITIZA collaboration ended in 2024, and while the verdict is not enforceable until court judgment, Takeda is adjusting its financial forecast and assessing the impact on its FY2026 adjusted free cash flow forecast.